dr. o'malley on toxicity profiles of parp inhibitors in ovarian cancer
Published 4 years ago • 97 plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
0:58
dr. o’malley on the optimal use of parp inhibitors in advanced ovarian cancer
-
1:18
dr. o'malley on the tolerability of parp inhibitors in ovarian cancer
-
1:08
dr. o'malley discusses the current role of parp inhibitors in ovarian cancer
-
1:15
dr. o’malley on the safety profile of mirvetuximab in ovarian cancer
-
5:53
adverse-effect profiles of parp inhibitors in ovarian cancer
-
2:30
dr. matulonis on toxicities with parp inhibitors in ovarian cancer
-
1:14
dr. o'malley discusses parp combinations in ovarian cancer
-
0:58
dr. o’malley on the utility of mirvetuximab in ovarian cancer
-
34:17
parp inhibitors for the treatment of ovarian cancer - gottfried konecny, md | uclamdchat
-
54:40
parp inhibitors in 2020: where are we now, and where are we going | webinar | ambry genetics
-
59:14
parp inhibitors in ovarian cancer: clinical updates from sgo 2023
-
1:09
dr. o’malley on research with immunotherapy in ovarian cancer
-
2:05
dr. coleman on the future of parp inhibitors in ovarian cancer
-
1:08
dr. o’malley on the state of immunotherapy in ovarian cancer
-
8:03
parp inhibitors in ovarian cancer: safety profile
-
1:15
dr. o’malley on remaining questions in ovarian cancer
-
6:39
difference among parp inhibitors for ovarian cancer
-
1:00
dr. o’malley on the forward ii phase ib study in ovarian cancer
-
1:10:07
optimizing the use of parp inhibitors in ovarian cancer
-
1:40
dr. hardesty on bevacizumab/parp inhibitor combination in ovarian cancer
-
1:47
dr. o’malley on antitumor activity with veliparib combo in serous ovarian cancer
-
1:54
dr. matulonis on toxicities with olaparib for patients with ovarian cancer